The present invention provides a nitric-oxide containing composite in the form of microparticles, wherein said microparticles comprise: (i) a core which comprises silica; (ii) a layer on said core which comprises a metal-organic framework; and (iii) nitric oxide;
wherein said metal-organic framework comprises organic ligands comprising at least one amine group, said metal-organic framework is uniformly distributed on the surface of said silica core and said nitric oxide is chemisorbed within said metal-organic framework.

A microparticle for drug loading, a drug loading microparticle, a particle containing tube, and an implantation system for the microparticle. The microparticle for drug loading includes a housing (31) and a drug loading part (34) located inside the housing and is used for being implanted into body tissues by means of a puncture needle (5); the housing (31) is provided with at least one micro-hole (33) running through the wall thickness of the housing (31); and the drug loading part (34) is located inside the housing (31) and is used for loading drugs. The microparticle for drug loading/drug loading microparticle can achieve different types of drug loading and different release speeds, can be directly implanted into tissues, and have the technical advantages of both microspheres and radioactive particles.

A microparticle for drug loading, a drug loading microparticle, a particle containing tube, and an implantation system for the microparticle. The microparticle for drug loading includes a housing (31) and a drug loading part (34) located inside the housing and is used for being implanted into body tissues by means of a puncture needle (5); the housing (31) is provided with at least one micro-hole (33) running through the wall thickness of the housing (31); and the drug loading part (34) is located inside the housing (31) and is used for loading drugs. The microparticle for drug loading/drug loading microparticle can achieve different types of drug loading and different release speeds, can be directly implanted into tissues, and have the technical advantages of both microspheres and radioactive particles.

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.

Methods, systems, compositions and strategies for the use of ARMM-mediated delivery of molecules (e.g., biological molecules, small molecules, proteins, and nucleic acids (e.g., DNA, RNA), DNA plasmids shRNA, mRNA) to cells of the nervous system (e.g., central nervous system and peripheral nervous system).

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.

The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

Methods of normalizing amino acid metabolism in subjects on restricted protein diets and supplemental amino acids, using specially formulated amino acids that mimic the absorption and metabolism of naturally occurring proteins, are described.

There is provided a process for the preparation of composition in the form of a plurality of particles having a weight-, number-, and/or volume-based mean diameter that is between amount 10 nm and about 700 μm, which particles comprise: (a) solid cores, preferably comprising a biologically active agent; and (b) two or more sequentially applied, discrete layers, each of which comprises at least one separately applied coating material, and which two or more layers together surround, enclose and/or encapsulate said cores, which process comprises the sequential steps of: (1) applying an initial layer of at least one coating material to said solid cores by way of a gas phase deposition technique; (2) discharging the coated particles from the gas phase deposition reactor and subjecting the coated particles to agitation to disaggregate particle aggregates formed during step (1) by way of mechanical sieving technique; (3) reintroducing the disaggregated, coated particles from step (2) into the gas phase deposition reactor and applying a further layer of at least one coating material to the reintroduced particles; and (1) optionally repeating steps (2) and (3) one or more times to increase the total thickness of the at least one coating material that enclose(s) said solid core. The gas phase deposition technique is preferably atomic layer deposition. When the cores comprise biologically active agent, the compositions may provide for the delayed or sustained release of said active agent without a burst effect.